In conclusion, the clinical intervention effect of afatinib targeted therapy in patients with non-small-cell lung cancer is significant, which not only helps to improve the patient's immune function but also effectively improves the patient's serum EGFR and pro-GRP levels and reduces the occurrence of adverse reactions, which can be widely used in clinical practice. This evidence concerns the gene EGFR and non-small cell lung carcinoma.